CD14: Biosynthesis, Trafficking and Secretion

CD14:生物合成、贩运和分泌

基本信息

项目摘要

DESCRIPTION (provided by applicant): Sepsis, a systemic inflammatory response to infection(l), is a major cause of death within the US. (1, 2) Therapy for sepsis is mainly supportive and frequently requires admission into intensive care units,(3) with a significant financial burden to the public health system.(4) Among the multiple etiologic factors triggering sepsis, infections by Gram (-) bacteria, rank as one of the most frequent. Lipopolysaccharide (LPS) is a key component of the cell wall of Gram (-) bacteria and a potent inducers of the inflammatory response (3). In fact, an overwhelming inflammatory response is responsible for the transition between sepsis and septic shock and subsequently multiple organ failure, which are responsible for the majority casualties from sepsis. The interaction of LPS with cells of the immune system, in particular macrophages (Mo), is via a complex between CDI4 and Toll-like receptor 4 (TLR4). In this complex, CD14 is the major binding site for LPS whereas TLR4 is involved in the signal transduction responsible for the inflammatory response. Recent findings from Dr. De Maio laboratory that have implicated the role of heat shock proteins (hsps) in the trafficking of CD14.(5) Treatment of a murine M0 line (J774 Cells) with Geldanamycin (GA), a specific inhibitor of Heat Shock protein - 90 (Hsp90) family, leads to increased internalization of the membrane bound form of CD14 (mCD14). Thus, Mos treated with GA show an impaired response to LPS.(5) In addition, GA is a potent inducer of the heat shock response.(6) Thus, the effect of GA on CD14 internalization could be due to inhibition of Hsp90 function or heat shock protein expression. These two hypotheses will be addressed in this project. Furthermore, CDM was observed to accumulate within the endoplasmic reticulum (ER) after GA treatment. Since Grp94 is the ER member of the Hsp90 family, its inhibition by GA may be responsible for CD14 ER accumulation, which could be due to the unfolding of this glycoprotein within the ER. in summary, this proposal aims to characterize the biosynthesis, ER retention, and trafficking of CDM after GA treatment. These studies may elucidate the role of hsps in these cellular processes.
描述(由申请人提供):败血症是一种对感染的全身性炎症反应,是美国主要的死亡原因。(1,2)脓毒症的治疗主要是支持性的,经常需要进入重症监护病房,(3)给公共卫生系统带来了重大的经济负担。(4)在引发脓毒症的多种病因中,革兰氏(-)菌感染是最常见的病因之一。脂多糖(LPS)是革兰氏(-)细菌细胞壁的关键成分,也是炎症反应的有效诱导剂(3)。事实上,压倒性的炎症反应是脓毒症和脓毒性休克之间的过渡以及随后的多器官衰竭的原因,这是脓毒症造成的大多数伤亡的原因。LPS与免疫系统细胞,特别是巨噬细胞(Mo)的相互作用是通过CDI4和toll样受体4 (TLR4)之间的复合物进行的。在这个复合体中,CD14是LPS的主要结合位点,而TLR4参与炎症反应的信号转导。De Maio博士实验室最近的发现暗示了热休克蛋白(hsps)在CD14运输中的作用。(5)用热休克蛋白- 90 (Hsp90)家族的特异性抑制剂格尔达霉素(GA)处理小鼠M0细胞系(J774细胞),导致CD14 (mCD14)膜结合形式的内化增加。因此,用GA处理的Mos对LPS的反应受损。(5)此外,GA是热休克反应的有效诱导剂。(6)因此,GA对CD14内化的影响可能是由于抑制Hsp90功能或热休克蛋白的表达。这两个假设将在这个项目中得到解决。此外,在GA治疗后,CDM被观察到在内质网(ER)内积累。由于Grp94是Hsp90家族的内质网成员,GA对其的抑制可能是导致CD14内质网积累的原因,这可能是由于内质网内这种糖蛋白的展开。总之,本研究旨在描述GA处理后CDM的生物合成、内质网保留和转运。这些研究可能阐明热休克蛋白在这些细胞过程中的作用。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Diego Fernando Nino其他文献

Diego Fernando Nino的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Diego Fernando Nino', 18)}}的其他基金

CD14: Biosynthesis, Trafficking and Secretion
CD14:生物合成、贩运和分泌
  • 批准号:
    8414422
  • 财政年份:
    2010
  • 资助金额:
    $ 3.19万
  • 项目类别:
CD14: Biosynthesis, Trafficking and Secretion
CD14:生物合成、贩运和分泌
  • 批准号:
    7810106
  • 财政年份:
    2010
  • 资助金额:
    $ 3.19万
  • 项目类别:
CD14: Biosynthesis, Trafficking and Secretion
CD14:生物合成、贩运和分泌
  • 批准号:
    8044030
  • 财政年份:
    2010
  • 资助金额:
    $ 3.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了